Antibacterial Drugs Market Size, Share, Growth, Analysis and Forecast 2016-2022Posted by johnson on January 4th, 2018 The latest market report published by Credence Research, Inc. “Global Antibacterial Drugs Market - Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 - 2022,” the antibacterial drugs market was valued at USD 42,232.2 Mn in 2015, and is expected to reach USD 45,909.4 Mn by 2022, expanding at a CAGR of 1.15% from 2016 to 2022. Browse the full report Antibacterial Drugs Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 at http://www.credenceresearch.com/report/antibacterial-drugs-market Market Insights Antibacterial drugs are derived from bacteria or molds or are synthesized de novo. These drugs treat infectious diseases caused by gram positive, gram negative, aerobic and anaerobic bacteria that cannot be treated by any other method unlike other diseases. Antibacterial drugs have several mechanisms of action, including inhibiting cell wall synthesis, increasing cell membrane permeability, interfering with protein synthesis, nucleic acid metabolism, and other metabolic processes. The alarming antibacterial-resistance crisis has penetrated the awareness of clinicians, researchers, policymakers, governments and the public at large. The key factors assisting the growth of antibacterial drugs market are mounting prevalence of infectious diseases, government support, and increased research and development activities. However, evolving drug-resistant species, launch of generics, and upcoming patent expirations are anticipated to restrict the growth of the global market through 2022. Globally, the rise in geriatric population is also being considered as one of the key growth factors as it will indirectly increase the demand for various antibacterial drugs. The demand for antibacterial drugs will continue to rise mainly due to increased prevalence of resistant species that demand development of innovative molecules. Click Here To Browse Report on Antibacterial Drugs Market: http://www.credenceresearch.com/report/antibacterial-drugs-market Pipeline Analysis The phase III drugs included in the pipeline analysis are solithromycin (Cempra, Inc.), VivaGel/ SPL7013 (Starpharma Holdings Limited), surotomycin (Merck & Co.), MK-3415A (Merck & Co.) and others. According to market experts, these upcoming drugs assure to provide enhanced efficacy, shorter onset of action and fewer side effects as compared to the currently available antibacterial drugs. Thus, future commercialization of these drugs during the forecast period 2016 – 2022 is anticipated to have a reflective impact on the growth of the overall antibacterial drugs market. Key Market Movements:
Table of Content Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Antibacterial Drugs Market: Market Dynamics and Outlook About Us: Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared for this task. Media Contact Like it? Share it!More by this author |